| abstract |
The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine composition of the present invention, when formulated with an adjuvant and a pharmaceutically acceptable carrier, induces a balanced tetravalent immune response, the truncated dengue in the form of a recombinantly produced monomer and / or dimer. Viral envelope glycoproteins. In a preferred embodiment of the composition described herein, the DEN4 protein component is DEN4 in dimeric form. The compositions are designed to be acceptable for use in the general population, including immunosuppressive, immunocompromised, and immunosenescent individuals. Also provided herein is a method of inducing a protective immune response in a human patient population by administering a composition described herein to a patient. |